BR0107618A - Pró-medicamentos solúveis em água de compostos de azol - Google Patents

Pró-medicamentos solúveis em água de compostos de azol

Info

Publication number
BR0107618A
BR0107618A BR0107618-3A BR0107618A BR0107618A BR 0107618 A BR0107618 A BR 0107618A BR 0107618 A BR0107618 A BR 0107618A BR 0107618 A BR0107618 A BR 0107618A
Authority
BR
Brazil
Prior art keywords
water
soluble
azole compounds
compounds
soluble prodrugs
Prior art date
Application number
BR0107618-3A
Other languages
English (en)
Inventor
Yasutsugu Ueda
John D Matiskella
Jerzy Golik
Thomas W Hudyma
Chung-Pin Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0107618A publication Critical patent/BR0107618A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymerization Catalysts (AREA)

Abstract

"PRó-MEDICAMENTOS SOLúVEIS EM áGUA DE COMPOSTOS DE AZOL". São fornecidos pró-medicamentos solúveis em água de compostos antifúgicos tiazol com um grupo hidroxi secundário ou terciário. Mais particularmente, são fornecidos novos compostos antifúngicos tiazol solúveis em água com a fórmula geral em que A é a parte não-hidroxi de um composto antifúngico triazol do tipo que tem um grupo hidroxila secundário ou terciária e R e R^ 1^ são bem definidos na especificação.
BR0107618-3A 2000-01-20 2001-01-16 Pró-medicamentos solúveis em água de compostos de azol BR0107618A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US24996900P 2000-11-20 2000-11-20
PCT/US2001/001284 WO2001052852A1 (en) 2000-01-20 2001-01-16 Water soluble prodrugs of azole compounds

Publications (1)

Publication Number Publication Date
BR0107618A true BR0107618A (pt) 2002-11-12

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107618-3A BR0107618A (pt) 2000-01-20 2001-01-16 Pró-medicamentos solúveis em água de compostos de azol

Country Status (22)

Country Link
US (1) US6362172B2 (pt)
EP (1) EP1284737B1 (pt)
JP (1) JP3766804B2 (pt)
KR (1) KR100748299B1 (pt)
CN (1) CN1178665C (pt)
AT (1) ATE300946T1 (pt)
AU (1) AU782177C (pt)
BR (1) BR0107618A (pt)
CA (1) CA2397734C (pt)
CZ (1) CZ20022822A3 (pt)
DE (1) DE60112433T2 (pt)
DK (1) DK1284737T5 (pt)
ES (1) ES2247131T3 (pt)
HU (1) HU229226B1 (pt)
IL (2) IL150798A0 (pt)
MX (1) MXPA02007120A (pt)
NO (1) NO330352B1 (pt)
NZ (1) NZ519354A (pt)
PL (1) PL206024B1 (pt)
PT (1) PT1284737E (pt)
RU (1) RU2266909C2 (pt)
WO (1) WO2001052852A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ES2432360T3 (es) * 2005-12-20 2013-12-03 Eisai R&D Management Co., Ltd. Procedimiento para la producción de profármaco de azol soluble en agua
EP2043446A2 (en) * 2006-02-08 2009-04-08 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
CN101389333A (zh) 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
RU2010151953A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Карбонатные продукты и способы их применения
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012060448A1 (ja) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2651450B1 (en) * 2010-12-16 2015-12-16 Borje S. Andersson Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR102044734B1 (ko) 2012-04-20 2019-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 캡슐 제형
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
ES2784307T3 (es) 2014-01-29 2020-09-24 Vyome Therapeutics Ltd Besifloxacina para el tratamiento del acné resistente
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
TW201718495A (zh) * 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
CA2111527C (en) 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
PL181193B1 (pl) 1993-12-21 2001-06-29 Schering Corp Nowe pochodne tetrahydrofuranowe o działaniu przeciwgrzybicznym, kompozycja farmaceutyczna do leczenia infekcji grzybiczych oraz sposób wytwarzania tych związków
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
SG48386A1 (en) 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
HUP9701690A3 (en) 1995-06-02 1998-04-28 Schering Corp Kenilwort Tetrahydrofuran derivatives as antifungals and pharmaceutical compositions containing the same
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
PT1056754E (pt) 1998-01-29 2004-03-31 Bristol Myers Squibb Co Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU1915500A (en) * 1998-11-20 2000-06-13 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Also Published As

Publication number Publication date
NO20023468L (no) 2002-07-29
DE60112433D1 (de) 2005-09-08
ES2247131T3 (es) 2006-03-01
WO2001052852A1 (en) 2001-07-26
DK1284737T5 (da) 2007-09-24
KR100748299B1 (ko) 2007-08-09
PL206024B1 (pl) 2010-06-30
EP1284737A1 (en) 2003-02-26
HU229226B1 (en) 2013-09-30
RU2266909C2 (ru) 2005-12-27
NO330352B1 (no) 2011-04-04
DE60112433T2 (de) 2006-05-18
EP1284737A4 (en) 2003-03-19
CZ20022822A3 (cs) 2003-02-12
CN1178665C (zh) 2004-12-08
AU782177C (en) 2007-10-18
ATE300946T1 (de) 2005-08-15
CN1395485A (zh) 2003-02-05
AU2948501A (en) 2001-07-31
JP2003520235A (ja) 2003-07-02
CA2397734A1 (en) 2001-07-26
CA2397734C (en) 2010-08-17
PL356164A1 (en) 2004-06-14
NO20023468D0 (no) 2002-07-19
DK1284737T3 (da) 2005-11-28
HUP0204405A3 (en) 2005-02-28
MXPA02007120A (es) 2003-01-28
KR20020070492A (ko) 2002-09-09
PT1284737E (pt) 2005-11-30
EP1284737B1 (en) 2005-08-03
JP3766804B2 (ja) 2006-04-19
US20010041691A1 (en) 2001-11-15
HUP0204405A2 (en) 2003-05-28
IL150798A0 (en) 2003-02-12
US6362172B2 (en) 2002-03-26
AU782177B2 (en) 2005-07-07
IL150798A (en) 2006-08-01
NZ519354A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
BR0107618A (pt) Pró-medicamentos solúveis em água de compostos de azol
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
AU7278500A (en) Fungicides
BRPI0402451A (pt) Compostos colorantes
ATE368049T1 (de) Nukleotidderivate mit einer reportergruppe und einer polymerase-enzym-blockierende gruppe
WO2001025227A3 (fr) Derives de la quinolyl propyl piperidine et leur utilisation en tant que antibacteriens
WO2002004422A3 (en) Heterocycle carboxamides as antiviral agents
BR9801122A (pt) Fecho rápido para a montagem de um cilindro de meio de pressão em uma caixa
EP0945764A3 (en) Photoresist composition
WO2002094020A8 (de) Verwendung von triazolopyrimidin-derivaten als mikrobizide im materialschutz
BR0115448A (pt) Processo para compostos azóis solúveis em água
BR0109542A (pt) Derivados de imidazopirina alquilados
WO1998002149A3 (en) Use of idebenone and analogues against beta amyloid induced cytotoxicity
CA2355533A1 (en) Colorant compounds, phase change ink compositions and methods of printing
EP0900785A3 (en) Vitamin A related compounds and process for producing the same
IE831840L (en) Cardiotonic agents
JO2691B1 (en) Monolysine salts for azole compounds
BR0107204A (pt) Inibidores da angiogênese de hidrazida e alcoxiamida
WO2001079268A3 (en) A glycopeptide and preparation thereof
MXPA03002081A (es) Accesorios quirales de 4-ciclohexil-1, 3, 2-oxazaborolidina.
BRPI0407191A (pt) Módulo de instalação
BG102578A (en) 1,3-oxazin-4-on derivatives as herbicides
WO2002051822A3 (en) Isothiazolecarboxamides as microbicides
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations
WO2001064169A3 (en) Antiplaque oral composition

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI CO., LTD. (JP)

Free format text: TRANSFERIDO DE: BRISTOL-MYERS SQUIBB COMPANY

B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]